Physician profile
Joseph E Cassara
NPI 1275755290
$5,665.33
in general payments reported to CMS, 2019-2025
28 companies · $2,234 in 2025
The $2,234 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.21 · 2022: $744 · 2023: $1,124 · 2024: $1,552 · 2025: $2,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,575 · Grant: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,574.61 |
| Grant | $335.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,598.72 | 2022-2025 | Linzess, Skyrizi, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $591.17 | 2022-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $415.17 | 2022-2025 | Stelara, Tremfya, Remicade |
| Regeneron Healthcare Solutions, INC. | $358.82 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $351.61 | 2023-2025 | |
| Genzyme Corporation | $257.60 | 2023-2025 | |
| Madrigal Pharmaceuticals | $248.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Boston Scientific Corporation | $247.97 | 2022-2023 | Exalt Model D |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $208.41 | 2023-2025 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $200.59 | 2024-2025 | Voquezna |
| Celgene Corporation | $156.10 | 2022-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $150.72 | 2024-2025 | Zenpep |
| Novo Nordisk INC | $120.89 | 2025 | Ozempic |
| E.R. Squibb & Sons, L.L.C. | $110.67 | 2022 | |
| Intercept Pharmaceuticals, INC. | $109.69 | 2022-2024 | Ocaliva |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $91.76 | 2025 | Omvoh |
| Braintree Laboratories, INC. | $72.91 | 2022-2025 | Suflave |
| Celltrion USA INC. | $57.63 | 2024-2025 | Vegzelma |
| Ardelyx, INC. | $55.93 | 2023-2024 | Ibsrela |
| Qol Medical, LLC | $55.84 | 2024-2025 | Sucraid, Sucraid |
| Organon LLC | $50.92 | 2024 | |
| Pfizer INC. | $39.36 | 2022-2024 | |
| Ipsen Biopharmaceuticals, INC | $26.96 | 2025 | Iqirvo |
| Mirum Pharmaceuticals, INC. | $23.54 | 2025 | Livmarli |
| Amgen INC. | $19.99 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.14 | 2023 | Cyltezo |
| Nestle Healthcare Nutrition INC. | $14.25 | 2022 | |
| Olympus America INC. | $12.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Cassara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.